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Background
The increasing burden of heart failure (HF) is a major
unmet need for new therapeutics. No new drug has
been approved for HF for over a decade. The natriuretic
peptides as endogenous activators of particulate guanylyl
cyclase (GC) receptors represent an unparalleled oppor-
tunity for novel therapeutic agents for HF. Specifically,
the GC-A receptor activated by ANP and BNP and GC-
B activation by CNP mediate beneficial pleiotropic
actions, which include natriuresis, vasodilatation, sup-
pression of the renin-angiotensin-aldosterone system,
inhibition of cardiomyocyte hypertrophy, retardation of
fibrosis and improvement in ventricular function and
structure.
Results
CD-NP (Cenderitide) represents the first in class
designer natriuretic peptide which co-activates both
GC-A and GC-B. Through rational drug design to co-
activate GC-A and GC-B together with increased resis-
tance to peptidase degradation, CD-NP possesses actions
which make CD-NP an innovative protein therapeutic to
target the heart, kidney, vasculature and endocrine sys-
tem in HF to reduce rehospitalization following acute
decompensated HF.
Conclusion
Here we review the biology, preclinical development and
recent human studies advancing CD-NP as a chronic
peptide therapeutic designer peptide to reduce the risk
of rehospitalization in human chronic HF.
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